A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care
Journal of Hospice and Palliative Nursing – December 19, 2024
Source: OpenAlex
Summary
Psychedelic-assisted therapy shows initial promise for addressing profound psycho-spiritual-existential distress in palliative care. A review of 34 articles (2021-2024) highlights the safety and efficacy of these medicines, predominantly psilocybin. Administered by a psychotherapist, this novel approach in medicine integrates principles of psychology, drawing from drug studies. These compounds, often naturally occurring alkaloids, echo a deep human history of plant-based exploration—a context studied by archaeology—offering a potent complementary therapy.
Abstract
Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence suggests possible utility of PAT for addressing psychosocial-spiritual-existential concerns, yet gaps remain in understanding findings related to PAT's role in palliative care. This rapid review aims to synthesize current literature on applications of PAT in the context of palliative care. Through a systematic process, we identified 34 articles published between January 2021 and July 2024. Protocols varied yet included common components of participant screening, preparation, dosing, and integration. Psilocybin was the most commonly studied compound. Results support safety and initial efficacy of PAT for psycho-spiritual-existential outcomes among carefully screened and highly homogonous samples of patients with serious illness (predominantly cancer). Current efforts and challenges around integrating PAT into systems of palliative care were highlighted. Additional work is needed to (1) explore PAT's safety and efficacy within more diverse samples and contexts, (2) train palliative care providers on PAT, (3) determine systems of care delivery best suited for translation of PAT into practice, and (4) begin developing policy solutions to support safe and equitable access to PAT. Because many patients lack access to basic psychosocial-spiritual-existential care, careful consideration is needed around integration of PAT. The psychedelic substances which are the topic of this article are not currently FDA approved for use in the United States.